Foghorn Therapeutics
FHTXFoghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of precision medicines that target the chromatin regulatory system.
Table of contents
Earnings
Next report
Aug 4, 2026 (In 6 days)Competitors
By market cap
By revenue growth
Profile
Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of precision medicines that target the chromatin regulatory system. By correcting abnormal gene expression, the company aims to treat serious diseases, primarily in oncology, with potential applications in immunology and inflammation. Their approach leverages a proprietary platform to identify and drug targets within the chromatin system that were previously considered untreatable.
Foghorn is a pioneer in the chromatin regulatory space, utilizing its proprietary Gene Traffic Control platform to target the BAF complex and other chromatin remodeling systems at scale.
Questions, answered.
- What is Foghorn Therapeutics's market cap?
- Foghorn Therapeutics (FHTX) has a market capitalization of $305.3M and trades on NASDAQ.
- Who are Foghorn Therapeutics's competitors?
- Foghorn Therapeutics's key competitors include Relay Therapeutics, Revolution Medicines, Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Foghorn Therapeutics partner with?
- Foghorn Therapeutics's notable partners include Eli Lilly and Company.
- Where is Foghorn Therapeutics headquartered?
- Foghorn Therapeutics is headquartered in United States of America and employs approximately 116 people. It has been publicly traded since 2020.